Pacific Biosciences of California (PACB) Competitors $1.44 -0.03 (-1.71%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIOShould you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO). Pacific Biosciences of California vs. Its Competitors 10x Genomics Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bio-Rad Laboratories 10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability. Which has stronger valuation & earnings, TXG or PACB? 10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$624.66M2.42-$182.63M-$1.30-9.44Pacific Biosciences of California$154.01M2.80-$309.85M-$2.79-0.51 Which has more risk & volatility, TXG or PACB? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Is TXG or PACB more profitable? 10x Genomics has a net margin of -25.14% compared to Pacific Biosciences of California's net margin of -430.93%. 10x Genomics' return on equity of -23.22% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Pacific Biosciences of California -430.93%-52.07%-15.82% Do insiders & institutionals have more ownership in TXG or PACB? 84.7% of 10x Genomics shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer TXG or PACB? In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 4 mentions for 10x Genomics and 3 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 1.10 beat 10x Genomics' score of 0.65 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TXG or PACB? 10x Genomics currently has a consensus target price of $14.13, suggesting a potential upside of 15.12%. Pacific Biosciences of California has a consensus target price of $2.06, suggesting a potential upside of 43.63%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46Pacific Biosciences of California 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Summary10x Genomics beats Pacific Biosciences of California on 10 of the 16 factors compared between the two stocks. Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PACB vs. The Competition Export to ExcelMetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$430.62M$6.61B$5.51B$9.34BDividend YieldN/A1.28%4.59%4.02%P/E Ratio-0.5126.0828.6719.68Price / Sales2.8042.59363.5974.53Price / CashN/A20.6824.7327.56Price / Book0.784.648.185.58Net Income-$309.85M$174.76M$3.24B$257.73M7 Day Performance-4.33%-2.78%2.33%1.30%1 Month Performance19.58%0.39%8.35%11.00%1 Year Performance-11.42%3.84%28.79%15.91% Pacific Biosciences of California Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PACBPacific Biosciences of California1.8483 of 5 stars$1.44-1.7%$2.06+43.6%-13.1%$430.62M$154.01M-0.51730Positive NewsTXG10x Genomics4.4751 of 5 stars$11.92-8.4%$14.96+25.5%-28.7%$1.47B$610.78M-9.171,240Positive NewsAnalyst ForecastHBIOHarvard Bioscience4.2562 of 5 stars$0.44-2.2%$3.00+577.2%-86.8%$19.59M$94.14M-0.34490TMOThermo Fisher Scientific4.9925 of 5 stars$418.76-2.5%$604.05+44.2%-22.4%$158.08B$42.88B24.56125,000Positive NewsDividend AnnouncementAAgilent Technologies4.783 of 5 stars$119.21-1.8%$140.92+18.2%-9.2%$33.86B$6.51B29.4317,900MTDMettler-Toledo International4.0224 of 5 stars$1,188.28-1.7%$1,300.36+9.4%-12.1%$24.69B$3.87B29.6317,300Positive NewsWATWaters4.8189 of 5 stars$346.35-1.1%$388.00+12.0%+0.5%$20.61B$2.96B31.437,600Trending NewsAnalyst ForecastILMNIllumina4.8551 of 5 stars$97.15-3.6%$127.39+31.1%-15.1%$15.38B$4.37B-16.009,030TECHBio-Techne4.8866 of 5 stars$51.54-3.0%$72.00+39.7%-31.9%$8.08B$1.16B62.853,100News CoverageCRLCharles River Laboratories International4.8385 of 5 stars$153.93-2.0%$171.85+11.6%-26.9%$7.56B$4.05B-236.8220,100Positive NewsBIOBio-Rad Laboratories4.6875 of 5 stars$247.45-1.6%$324.25+31.0%-17.5%$6.73B$2.57B-3.257,700News CoverageAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies TXG Competitors HBIO Competitors TMO Competitors A Competitors MTD Competitors WAT Competitors ILMN Competitors TECH Competitors CRL Competitors BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PACB) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
